Lantern Pharma Inc.
LTRN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $34,080 | $38,178 | $34,403 |
| - Cash | $8,389 | $6,061 | $6,378 | $7,511 |
| + Debt | $0 | $145 | $195 | $244 |
| Enterprise Value | – | $28,163 | $31,995 | $27,136 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$4 | $0 | $0 | -$51 |
| % Margin | – | – | – | – |
| EBITDA | -$4,173 | -$4,647 | -$4,769 | -$5,824 |
| % Margin | – | – | – | – |
| Net Income | -$4,177 | -$4,331 | -$4,537 | -$5,875 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.39 | -0.4 | -0.42 | -0.54 |
| % Growth | 2.5% | 4.8% | 22.2% | – |
| Operating Cash Flow | -$4,572 | -$3,937 | -$4,376 | -$3,972 |
| Capital Expenditures | -$1 | -$0 | -$1 | -$3 |
| Free Cash Flow | -$4,573 | -$3,937 | -$4,377 | -$3,975 |